# Company Analysis
This section aims to analyse companies in the pharmaceutical industry. 



## [Novartis]
Novartis was created through a merger of two Basel-based Swiss entities, Ciba-Geigy and Sandoz, both with roots extending back to the 19th century. 
Its earliest predecessor started out as a chemicals and dyes trading company back in 1758 and nowadays Novartis is one of the leading pharmaceutical companies in the industry.


### 2019
According to Novartis' annual report from 2019, their strategy strategy is to build a leading, focused medicines company powered by advanced therapy platforms and data science. 

Novartis sets five priorities to shape their future and help them continue to create value for their company, their shareholders and society. 
1. unleash the power of our people;
2. deliver transformative innovation;
3. embrace operational excellence;
4. go big on data and digital;
5. and build trust with society.


The Group comprises **two** global operating divisions:
• **Innovative Medicines**: innovative patent-protected prescription medicines
• **Sandoz**: generic pharmaceuticals and biosimilars

### 2023 
Novartis focuses on four core therapeutic areas with strong growth potential and high unmet patient needs: 

1. Cardiovascular
2. Renal and metabolic
3. Immunology
4. Neuroscience
5. Oncology (sales growth was mainly driven by Kisqali, Pluvicto, Scemblix and Promacta/Revolade)


Beginning in September 2023, Novartis reorganized its operations into the following five organizational units:

- **Biomedical Research** is our innovation engine, focused on creating new ways of fighting disease and turning scientific breakthroughs into new medicines with the potential to change lives.
- **Development** oversees the development of potential new medicines through clinical trials to confirm theirsafety and efficacy, and steers the way to regulatory approval for use by patients.
- **Operations** manufactures and delivers our medicines to customers, while also overseeing the global functions of IT, procurement and real estate services.
- The two commercial units, **US** and **International**, focus on their respective geographic areas. They work with customers to provide innovative medicines and services that improve treatment options and raise the quality of care for patients. 


## [Lonza]
Effective 31 May 2023, Lonza Group acquired 100% of the shares of Synaffix B.V., Netherlands for an initial cash consideration of EUR 107 million and an additional performance-based consideration up to EUR 60 million. Synaffix is an innovative biotech company focused on antibody-drug conjugates (ADCs). The acquisition will further strengthen
Lonza’s bioconjugates offering through the integration of Synaffix technology platform
and R&D capabilities.

> [!WARNING]
> I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
> 
> All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
> 
> I will not and cannot be held liable for any actions you take as a result of anything you read here.
> 
> Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
